Dr. Nejat Egilmez Microbiology and Immunology 115 Biomedical Research Building Buffalo NY, 14214 Phone: (716) 829-2907 Email: negilmez@buffalo.edu View map

EDUCATION

1986	Ph.D., Cell and Molecular Biology State University of New York at Buffalo
1983	M.A., Cell and Molecular Biology State University of New York at Buffalo
1980	Bachelor of Science, Biochemistry University of Minnesota

PUBLICATIONS

Watkins SK, Egilmez NK, Suttles J, Stout RD; IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo.; J Immunol; 2007 Feb; 178(3); 1357-1362

Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK; Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.; J Immunol; 2006 Nov; 177(10); 6962-6973

Nair RE, Kilinc MO, Jones SA, Egilmez NK; Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.; J Immunol; 2006 Jun; 176(12); 7325-7334

Lou Q, Conway TF, Egilmez NK, Loyall JL, Bernstein SH, Kelleher RJ, Bankert RB; B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells.; Clin Immunol; 2006 Jan; 118(1); 66-76

Sabel MS, Hess SD, Egilmez NK, Conway TF, Chen FA, Bankert RB; CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice.; Cancer Immunol Immunother; 2005 Oct; 54(10); 944-952

Carvalho-Queiroz C, Cook R, Wang CC, Correa-Oliveira R, Bailey NA, Egilmez NK, Mathiowitz E, LoVerde PT; Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.; Infect Immun; 2004 May; 72(5); 2635-2647

Sabel MS, Skitzki J, Stoolman L, Egilmez NK, Mathiowitz E, Bailey N, Chang WJ, Chang AE; Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity.; Ann Surg Oncol; 2004 Feb; 11(2); 147-156

Anderson TM, Hess SD, Egilmez NK, Nwogu CE, Lenox JM, Bankert RB; Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes.; J Cancer Res Clin Oncol; 2003 Oct; 129(10); 565-568

Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH, Bankert RB; Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma.; J Immunol; 2003 Jan; 170(1); 400-412

Hill HC, Conway TF, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK; Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.; Cancer Res; 2002 Dec; 62(24); 7254-7263

Egilmez NK, Hess SD, Chen FA, Takita H, Conway TF, Bankert RB; Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice.; Cancer Res; 2002 May; 62(9); 2611-2617

Bankert RB, Hess SD, Egilmez NK; SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions.; Front Biosci; 2002 Apr; 7; 44-62

Sabel MS, Hill H, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK; Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases.; Surgery; 2001 Sep; 130(3); 470-478

Hess SD, Egilmez NK, Shiroko J, Bankert RB; Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.; Cancer Gene Ther; 2001 May; 8(5); 371-377

Yamada M, Shiroko T, Kawaguchi Y, Sugiyama Y, Egilmez NK, Chen FA, Bankert RB; CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors.; Int J Cancer; 2001 May; 92(4); 589-599

Bankert RB, Egilmez NK, Hess, S.D.; Human/SCID Chimeric Models for Pre-clinical Evaluation of Anti-Cancer Therapies: Applications, Limitations and Future Directions; Trends in Immunology; 2001; 22(7); 386-393

Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB; Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.; Cancer Res; 2000 Dec; 60(24); 6942-6949

Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB; In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.; Cancer Res; 2000 Jul; 60(14); 3832-3837

Cherkasova, V., Ayyadevara, S., Egilmez NK, Reis, R.S.; Diverse caenorhabditis elegans genes that are unregulated in dauer larvae also show elevated transcript levels in long-lived, aged, or starved adults; J. Mol. Biol.; 2000; 300(3); 433-448

Conway TF, Sabel MS, Sugano M, Frelinger JG, Egilmez NK, Chen F, Bankert RB; Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum.; J Immunol Methods; 2000 Jan; 233(1-2); 57-65

Kuriakose MA, Chen FA, Egilmez NK, Jong YS, Mathiowitz E, DeLacure MD, Hicks WL, Loree TL, Bankert RB; Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model.; Head Neck; 2000 Jan; 22(1); 57-63

Bankert RB, Chen, F-A, Sugiyama, Y, Egilmez NK; Patient immune response to tumors monitored using SCID mouse models; Immunol. Invest.; 2000; 29(2); 171-176

Jong, Y.S., Egilmez NK, Jacob, J.S., Smith, L.P., Mottl, T.S., Chen, F-A., Bankert RB, Mathiowitz, E.; Evaluation of cytokine delivery systems for cancer immunotherapy; Proc. Mater. Res. Soc., Implants and Tissue Engineering; 1999; 550; 71-75

Egilmez NK, Jong YS, Iwanuma Y, Jacob JS, Santos CA, Chen FA, Mathiowitz E, Bankert RB; Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model.; Cancer Immunol Immunother; 1998 Mar; 46(1); 21-24

Iwanuma Y, Chen FA, Egilmez NK, Takita H, Bankert RB; Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice.; Cancer Res; 1997 Jul; 57(14); 2937-2942

Egilmez NK, Cuenca R, Yokota SJ, Sorgi F, Bankert RB; In vivo cytokine gene therapy of human tumor xenografts in SCID mice by liposome-mediated DNA delivery.; Gene Ther; 1996 Jul; 3(7); 607-614

Egilmez NK, Iwanuma Y, Bankert RB; Evaluation and optimization of different cationic liposome formulations for in vivo gene transfer.; Biochem Biophys Res Commun; 1996 Apr; 221(1); 169-173

Egilmez NK, Ebert RH, Shmookler Reis RJ; Strain evolution in Caenorhabditis elegans: transposable elements as markers of interstrain evolutionary history.; J Mol Evol; 1995 Apr; 40(4); 372-381

Egilmez NK, Shmookler Reis RJ; Age-dependent somatic excision of transposable element Tc1 in Caenorhabditis elegans.; Mutat Res; 1994 Feb; 316(1); 17-24

Egilmez NK, Gokmen, Y., Bahcecioglu, H., Kirdar, B.; Human Factor VIII Hindlll Polymorphism: Genotypic Distribution in the Turkish Population; The Turkish Journal of Medical Sciences; 1992; 16; 105-112

Graham JB, Kunkel GR, Egilmez NK, Wallmark A, Fowlkes DM, Lord ST; The varying frequencies of five DNA polymorphisms of X-linked coagulant factor IX in eight ethnic groups.; Am J Hum Genet; 1991 Sep; 49(3); 537-544

Egilmez NK, Chen JB, Jazwinski SM; Preparation and partial characterization of old yeast cells.; J Gerontol; 1990 Jan; 45(1); 9-17

Egilmez NK, Chen JB, Jazwinski SM; Specific alterations in transcript prevalence during the yeast life span.; J Biol Chem; 1989 Aug; 264(24); 14312-14317

Egilmez NK, Jazwinski SM; Evidence for the involvement of a cytoplasmic factor in the aging of the yeast Saccharomyces cerevisiae.; J Bacteriol; 1989 Jan; 171(1); 37-42

Egilmez NK, Rothstein M; The effect of aging on cell-free protein synthesis in the free-living nematode Turbatrix aceti.; Biochim Biophys Acta; 1985 Jul; 840(3); 355-363

Egilmez NK, Jong YS, Hess SD, Jacob JS, Mathiowitz E, Bankert RB; Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model.; J Immunother; 23(2); 190-195

Sugiyama Y, Kato M, Chen FA, Williams SS, Kawaguchi Y, Miya K, Jong YS, Mathiowitz E, Egilmez NK, Bankert RB; Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12.; J Immunother; 24(1); 37-45

Egilmez NK, Bankert RB; Liposome-mediated cytokine gene delivery to human tumor xenografts.; Methods Enzymol; 373; 529-535

Jazwinski SM, Egilmez NK, Chen JB; Replication control and cellular life span.; Exp Gerontol; 24(5-6); 423-436

Abra RM, Bankert RB, Chen F, Egilmez NK, Huang K, Saville R, Slater JL, Sugano M, Yokota SJ; The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients.; J Liposome Res; 12(1-2); 1-3

Egilmez NK, Jong YS, Mathiowitz E, Bankert RB; Tumor vaccination with cytokine-encapsulated microspheres.; Methods Mol Med; 75; 687-696

GRANTS

April 2004 to March 2009 Integrating Innate and Adaptive Immunity in Cancer Therapy NIH Nejat Egilmez $1,205,000

July 2003 to June 2007 Biodegradable Microspheres for Cancer Immunotherapy NIH Nejat Egilmez $2,631,714

August 2001 to November 2005 Tumor vaccination with Cytokine-encapsulated Microspheres DOD Breat Cancer Program Nejat Egilmez $300,000

January 2000 to January 2003 Bioadhesive Microspheres for Colon cancer Therapy NIH Nejat Egilmez $415,600

to January 2002 Interleukin-10 Microspheres for Therapy of IBD NIH Nejat Egilmez $99,500

to December 2001 Intratumoral Injection of Biodegradable Polymer Microspheres Containing Recombinant Human Interleukin-12 for Cancer Immunotherapy Rapid Access to Intervention Development Program,NCI Nejat Egilmez